Iambic, an AI drug discovery specialist, has raised $150 million in an initial public offering, according to BioPharma Dive. The company is part of a growing wave of young biotechs using artificial intelligence to accelerate research.
In regulatory filings, Iambic said its approach has the potential to "disrupt legacy drug discovery paradigms." The company's platform aims to apply AI to the early stages of drug development, an area that has drawn significant investor interest in recent years.
The IPO adds to a string of similar listings as investors bet on AI's ability to reduce the time and cost of bringing new medicines to market. Whether Iambic can deliver on its promises remains to be seen, but the funding gives it resources to advance its pipeline.